Tech Company Financing Transactions
Callio Therapeutics Funding Round
Callio Therapeutics, operating out of Seattle, secured $187 million from Frazier Life Sciences, ClavystBio and Edbi.
Transaction Overview
Company Name
Announced On
3/3/2025
Transaction Type
Venture Equity
Amount
$187,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to expand operations and its development efforts.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Seattle, WA Undisclosed
USA
Seattle, WA Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
We are developing next-generation, multi-payload antibody-drug conjugates (ADCs) that feature differentiated payload and linker technologies. This enables targeted delivery of drug combinations to tumor cells to maximize therapeutic benefit for cancer patients. Our lead program is a dual-payload HER2-targeted ADC.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Piers Ingram
Browse more venture capital transactions:
Prev: 3/3/2025: Faks venture capital transaction
Next: 3/3/2025: Tevogen Bio venture capital transaction
Share this article
About Our Venture Capital Transactions Database
We do our best to report on every notable VC transaction. All VC database entries reported here come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs